Home Metabolism Dehydrogenase inhibitor BAY 1436032

research use only

BAY 1436032 Dehydrogenase inhibitor

Cat.No.S8530

BAY-1436032 is a highly selective, potent and orally available inhibitor of mutant Isocitrate Dehydrogenase 1 (mIDH1). It is a double-digit nanomolar and selective pan-inhibitor of the enzymatic activity of various IDH1-R132X mutants in vitro and displays potent inhibition of 2-HG release (nanomolar range) in patient derived and engineered cell lines expressing different IDH1 mutants.
BAY 1436032 Dehydrogenase inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 489.53

Jump to

Quality Control

Batch: S853001 DMSO]98 mg/mL]false]Ethanol]98 mg/mL]false]Water]Insoluble]false Purity: 99.78%
99.78

Solubility

In vitro
Batch:

DMSO : 98 mg/mL (200.19 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 98 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 489.53 Formula

C26H30F3N3O3

 Storage (From the date of receipt) 3 years -20°C powder
CAS No. 1803274-65-8 -- Storage of Stock Solutions

Synonyms N/A Smiles CC1CC(CC(C1)(C)C)N2C3=C(C=C(C=C3)CCC(=O)O)N=C2NC4=CC=C(C=C4)OC(F)(F)F

Mechanism of Action

Targets/IC50/Ki
IDH1 (R132H)
(Cell-free assay)
15 nM
IDH1 (R132C)
(Cell-free assay)
15 nM
In vitro

BAY 1436032 exhibits an IC50 of 15 nM for mutant IDH1R132H protein and virtually no effect on wild-type IDH1 and the structurally related IDH2 proteins with IC50 of 20 and >100 µM, respectively. This compound not only reduces 2-HG levels in cells with the IDH1R132H or the IDH1R132C mutations, but also in those with the R132G, R132S or R132L mutations with equal efficiency. There is no inhibition of IDH2 R172M. This chemical reduces proliferation and induces differentiation in primary glioma cultures. It reveals low metabolic clearance (CL) in vitro in rat hepatocytes and mice liver microsomes.
In vivo

The pharmacokinetic properties of BAY 1436032 allow for oral administration. In vivo pharmacokinetics (PK) in rats shows low CL and high oral bioavailability. Oral administration of this compound confers a survival benefit to mice transplanted with IDH1 mutant tumors. This chemical induces differentiation in intracranial xenografts.
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03127735 Completed
Leukemia Myeloid Acute
Bayer
 June 14 2017 Phase 1
NCT02746081 Active not recruiting
Solid Tumors
Bayer
 May 26 2016 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map